Reunion Neuroscience (NASDAQ:REUN – Get Rating) and aTyr Pharma (NASDAQ:LIFE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends. Analyst Recommendations This is a breakdown of recent recommendations […]
Avidity Partners Management LP lessened its holdings in Reunion Neuroscience Inc. (NASDAQ:REUN – Get Rating) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 560,300 shares of the company’s stock after selling 34,900 shares during the quarter. Avidity Partners Management LP […]
Bloom Burton downgraded shares of Reunion Neuroscience (NASDAQ:REUN – Get Rating) from a buy rating to a hold rating in a report issued on Thursday morning, PriceTargets.com reports. REUN has been the topic of a number of other research reports. HC Wainwright restated a buy rating and set a $20.00 target price on shares of […]
ThinkEquity initiated coverage on shares of Reunion Neuroscience (NASDAQ:REUN – Get Rating) in a research note published on Monday morning, The Fly reports. The firm issued a buy rating on the stock. A number of other analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a buy rating and set a $20.00 […]
Equities researchers at ThinkEquity began coverage on shares of Reunion Neuroscience (NASDAQ:REUN – Get Rating) in a note issued to investors on Monday, The Fly reports. The brokerage set a “buy” rating on the stock. Several other equities research analysts also recently commented on the stock. EF Hutton Acquisition Co. I reaffirmed a “buy” rating […]